Difficulty: Medium
Average Score: 64%
Practice
Which of the following should not be administered to a patient with myasthenia gravis?
Correct answer
D
Rationale
In the context of CNS stimulants drugs pharmacology, it is crucial to understand the implications of administering certain medications to patients with specific conditions like myasthenia gravis. Myasthenia gravis is an autoimmune neuromuscular disorder characterized by muscle weakness and fatigue.
The correct answer, D) Curare, should not be administered to a patient with myasthenia gravis because curare is a neuromuscular blocking agent that can exacerbate muscle weakness in these patients. Since myasthenia gravis already affects neuromuscular transmission, adding a drug like curare can significantly worsen the condition.
A) Prostigmine is an acetylcholinesterase inhibitor commonly used to treat myasthenia gravis by increasing acetylcholine levels at the neuromuscular junction, improving muscle function. B) Digitalis is a medication used in heart conditions like heart failure and atrial fibrillation, not directly contraindicated in myasthenia gravis. C) Atropine is an anticholinergic drug that blocks the action of acetylcholine and is generally avoided in myasthenia gravis due to its potential to worsen muscle weakness.
Educationally, this question highlights the importance of considering a patient's underlying conditions when prescribing medications, especially in pharmacology where drug interactions and contraindications play a significant role in patient outcomes. It emphasizes the need for healthcare professionals to have a thorough understanding of both the pharmacology of drugs and the pathophysiology of various diseases to make safe and effective treatment decisions.
The correct answer, D) Curare, should not be administered to a patient with myasthenia gravis because curare is a neuromuscular blocking agent that can exacerbate muscle weakness in these patients. Since myasthenia gravis already affects neuromuscular transmission, adding a drug like curare can significantly worsen the condition.
A) Prostigmine is an acetylcholinesterase inhibitor commonly used to treat myasthenia gravis by increasing acetylcholine levels at the neuromuscular junction, improving muscle function. B) Digitalis is a medication used in heart conditions like heart failure and atrial fibrillation, not directly contraindicated in myasthenia gravis. C) Atropine is an anticholinergic drug that blocks the action of acetylcholine and is generally avoided in myasthenia gravis due to its potential to worsen muscle weakness.
Educationally, this question highlights the importance of considering a patient's underlying conditions when prescribing medications, especially in pharmacology where drug interactions and contraindications play a significant role in patient outcomes. It emphasizes the need for healthcare professionals to have a thorough understanding of both the pharmacology of drugs and the pathophysiology of various diseases to make safe and effective treatment decisions.